Cartalax

Cartalax is a cartilage-tissue peptide bioregulator from the Russian short-peptide bioregulator platform associated with Vladimir Khavinson and colleagues. Its active synthetic short peptide is the tripeptide Ala-Glu-Asp, abbreviated AED. Early work on a sequence-extended variant, Ala-Glu-Asp-Arg (AEDR), showed the Ala-Glu-Asp core stimulates expression of cytoskeletal and nuclear matrix proteins, establishing it as a matrix-signaling motif ⁶.

Cartalax is investigated for cartilage extracellular-matrix support, chondrocyte aging, and connective-tissue repair. In replicatively aged human mesenchymal stem cells (MSCs), the cells that can mature into cartilage-forming chondrocytes, AED activates the gene program that builds cartilage matrix ¹. In aged chondrocytes, AED normalizes the senescence-associated inflammatory output and restores the protective sirtuin Sirt1 ².

What it is studied for

• Cartilage repair through chondrogenic differentiation in aged human stem cells ¹
• Osteoarthritis-relevant chondrocyte aging, through normalization of the senescence-associated secretory phenotype ²
• Fibroblast aging and collagen synthesis in human skin cells ³
• Stem-cell gene-expression modulation, including IGF1, TERT, and FOXO1 ⁴
• Neuronal differentiation, only as part of a peptide compound, with weak evidence ⁵

The evidence base is entirely in-vitro work on human cells. No human clinical trials of Cartalax exist in the published literature, and research is dominated by one network, the St. Petersburg bioregulator school, with limited independent replication.

Cartalax is not a receptor agonist. It works as a transcriptional and epigenetic regulator inside cartilage-forming and cartilage-resident cells, steering aged chondrocytes and mesenchymal stem cells away from senescence and inflammatory signaling and back toward the gene program that builds cartilage matrix ¹.

The SOX9 axis

In human MSCs undergoing replicative aging, AED at 200 ng/mL increases gene and protein expression of SOX9, the master transcription factor for cartilage development, along with aggrecan, type II collagen (COL2A1), and COMP (cartilage oligomeric matrix protein) ¹. This SOX9 to COL2A1, aggrecan, and COMP axis is the direct molecular output behind the repair signal. For comparison, the cartilage polypeptide complex CPC required 2,000 ng/mL, ten times higher, for the same effect ¹.

Quieting the aging chondrocyte

Aging chondrocytes overproduce senescence and inflammatory signals (p16, p21, p53, TNF-α, IL-1α) while losing Sirt1. AED normalizes these markers and restores Sirt1 synthesis. Researchers call this normalizing the senescence-associated secretory phenotype, or SASP, and interpret it as the geroprotective basis for an osteoarthritis application ².

How a short peptide reaches genes

AED is presumed to act by direct DNA and histone interaction rather than a membrane receptor. Class-level data show related short bioregulators, including Cortagen (Ala-Glu-Asp-Pro), which shares the Ala-Glu-Asp motif, selectively decondense tightly packed chromatin and reactivate silenced genes in lymphocytes from donors aged 75 to 88 ⁶. By this logic, Cartalax restores transcriptional access to chondrogenic genes that were silenced during aging.

Beyond cartilage

AED also activates sirtuin-1 and sirtuin-6 and stimulates collagen I synthesis in replicatively aged human skin fibroblasts ³. With related peptides KED and KE, it modulates IGF1, TERT, FOXO1, TNKS2, and NF-κB in human bone-marrow MSCs at nanomolar concentrations, with IGF1 expression enhanced 3.5 to 5.6-fold ⁴. The repair signature appears to extend beyond cartilage to general connective tissue.

Every published efficacy finding for Cartalax comes from in-vitro work on human cells. The documented effects fall into four groups, ordered from most to least direct.

• Chondrogenic differentiation. AED at 200 ng/mL activated gene and protein expression of SOX9, aggrecan, type II collagen, and COMP in replicatively aged human MSCs. The cartilage polypeptide complex CPC required 2,000 ng/mL for the same effect, making AED roughly ten times more potent on a mass basis ¹.
• Chondrocyte SASP normalization. AED and CPC normalized p16, p21, p53, TNF-α, and IL-1α while restoring Sirt1 in aged chondrocytes, reversing the inflammatory secretory program that drives cartilage degradation ².
• Connective-tissue matrix anabolism. In replicatively aged human skin fibroblasts, AED activated sirtuin-1, sirtuin-6, and collagen I synthesis. The profile is matrix-building rather than broadly anti-inflammatory ³.
• Broad gene modulation. At nanomolar concentrations, AED with related peptides KED and KE modulated IGF1 (3.5 to 5.6-fold upregulation), FOXO1, TERT, TNKS2, and NF-κB across two human MSC aging models, suggesting a systemic regulatory mechanism ⁴.
• Stem-cell differentiation support, weak. As part of a four-peptide compound, AED contributed to increased GAP43 and Nestin expression in human periodontal ligament stem cells, but its individual contribution was not isolated ⁵.

What does not exist is equally important: no randomized controlled trials, no in-vivo osteoarthritis models, and no human symptom or imaging outcomes for AED appear in the published literature. Human efficacy is unquantified, and the strongest claims stop at what happens in a culture dish.

The published literature characterizes Cartalax's functional constituents, AED and CPC, only in cell culture, and no controlled human dosing trials exist ¹. Current dosing patterns are practitioner and community conventions layered on the in-vitro activity profiles.

In-vitro anchors

The key published concentrations: AED at 200 ng/mL activates the chondrogenic gene program in human MSCs, while CPC needs 2,000 ng/mL for the same endpoints ¹. Nanomolar AED-family concentrations modulate aging-related gene expression in MSC models ⁴. These culture concentrations are not directly convertible to human doses; they indicate the peptide family acts across a wide, non-linear range rather than through dose-proportional mass effects.

Community and practitioner courses

Research and community protocols typically run short, intermittent courses:

• Oral capsules: 10 to 20 mg total daily, split once or twice per day, for 10 to 30 days, repeated 2 to 3 courses per year with gaps of at least 4 months.
• Injectable: 5 to 10 mg once daily by subcutaneous or intramuscular route for 10 days, repeated every 3 to 6 months.
• Combined: a 10-day injectable course followed by an oral continuation of 10 to 20 mg per day, about 30 days total, twice per year.

Flat dosing rather than body-weight scaling is the convention, on the reasoning that short peptides act as gene-expression signaling templates. Community reports describe slow, cumulative subjective effects: reduced morning stiffness at 2 to 4 weeks, with peak benefit 4 to 8 weeks after a course completes, consistent with matrix synthesis accumulating after the signaling phase ¹.

Cartalax injectable material is lyophilized (freeze-dried) AED powder supplied in vials. Reconstitution follows standard peptide practice: a diluent is added, the vial is mixed gently, and the finished solution is kept cold. The interactive calculator in this section works out the volume for any desired dose.

Diluent choice

Bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative, is the standard diluent for a multi-dose vial. Sterile water without preservative is used only for single-dose administration or when there is a sensitivity to benzyl alcohol.

Mixing technique

The diluent is injected slowly against the vial wall, and the vial is swirled gently. Shaking is avoided because it risks shear-induced aggregation of the peptide. The finished solution should be clear and colorless. Cloudiness, particles, or a color change are reasons to discard the vial.

Storage and shelf life

Lyophilized powder is stored long-term at -20°C, desiccated and protected from light, with short-term storage at 2 to 8°C acceptable for weeks and room temperature limited to brief handling. Reconstituted solution is refrigerated at 2 to 8°C and protected from light. With bacteriostatic water the solution is used within 14 to 30 days; with sterile water, within 24 to 48 hours. Avoid repeated freeze-thaw cycles, and draw each dose at the point of use because peptides can adsorb to plastic.

No published human drug-drug interaction studies exist for Cartalax. The interaction picture below is mechanism-based, with practitioner positions noted as such.

Drug classes

• NSAIDs and corticosteroids. Cartalax normalizes chondrocyte TNF-α and IL-1α output ². Strong anti-inflammatories can mask symptom improvement while structural disease continues, so practitioner convention monitors joint function rather than pain alone.
• Anticoagulants and antiplatelets. No published hemostasis data exist for AED specifically, and no mechanism supports added bleeding risk. Standard monitoring applies.
• DMARDs and biologics (anti-TNF, anti-IL-1). Theoretical overlap on TNF-α and IL-1α pathways ² suggests possible additive effect, with no evidence of antagonism. Prescribed DMARDs should not be replaced.
• Local anesthetics. No compatibility data exist; mixing in the same syringe is avoided unless pharmacy compatibility is confirmed.

As a short peptide, Cartalax is expected to undergo proteolytic degradation rather than liver CYP metabolism.

Supplements

• Glucosamine, chondroitin, MSM, and collagen hydrolysate are common joint-stack partners with no known conflict; they supply matrix precursors while the peptide signal drives matrix gene expression ¹.
• Omega-3 fatty acids add a theoretical anti-inflammatory effect via TNF-α and IL-1α reduction ², and retain their own antiplatelet activity.
• Vitamin C is a collagen synthesis cofactor and is mechanistically complementary to collagen induction ¹.

Peptide combinations

• Cartalax with Epitalon (AEDG). A common practitioner stack for age-related musculoskeletal decline; Epitalon has broad geroprotective and neuroendocrine actions, and no cartilage-specific interaction data exist.
• Cartalax with BPC-157 or TB-500. A common community repair stack for joint and tendon injury with no published interaction data; mechanistic overlap on matrix and cytoskeletal pathways is plausible but unverified.
• Cartalax with other cartilage complexes (CPC). Redundant targeting of the same SASP and chondrogenic pathways ¹, with no rationale for concurrent use.

The published literature does not describe tolerance or desensitization to Cartalax, and community practice treats cycling as part of the protocol rather than an accessory. Practitioner tiers range from 10-day to 30-day injectable courses separated by 1 to 3-month off periods, repeated 2 to 3 times per year; oral courses of 10 to 30 days follow similar timing.

The rationale is mechanistic. AED normalizes the chondrocyte senescence program, decreasing p16, p21, p53, TNF-α, and IL-1α while increasing Sirt1 ², and upregulates sirtuin-1, sirtuin-6, and collagen I in fibroblasts ³. Once those markers are normalized, continued peptide input has nothing further to correct. Class-level work shows related bioregulators selectively remodel specific condensed chromatin regions in lymphocytes from 75-to-88-year-old donors, an effect treated as a reset rather than a chronic therapy ⁷.

Off periods are considered part of the intervention. Community break signals include a plateau in joint comfort and mobility after 4 to 6 weeks of a course, relief that now requires continuous dosing between courses, new injection-site reactions, or new swelling or effusion in a targeted joint. Resumption after a break conventionally returns to a standard rather than an intensive course unless the prior course produced no measurable effect.

Cartalax is commonly stacked with two families of compounds in community and practitioner practice: other Khavinson short-peptide bioregulators, and repair peptides aimed at joint and connective tissue.

• With Epitalon (AEDG). Epitalon is the pineal bioregulator of the same family, with geroprotective, antioxidant, and neuroendocrine actions demonstrated in human biomarker work ¹⁰. Practitioners pair it with Cartalax for age-related musculoskeletal decline, with Cartalax addressing the cartilage and Epitalon the systemic aging axis. The mechanisms do not directly overlap, and no conflict is documented.
• With BPC-157 and TB-500. This is the most common repair stack in community practice for joint and tendon injury. No published interaction data exist, and mechanistic overlap on matrix and cytoskeletal pathways is plausible but unverified.
• With AED-family peptides (KED, KE). AED, KED, and KE jointly modulate IGF1, FOXO1, TERT, TNKS2, and NF-κB in human MSCs at nanomolar concentrations ⁴. Stacking more than one peptide aimed at the same MSC and matrix pathways has no added-effect evidence.
• With joint supplements. The matrix-building signal (SOX9, aggrecan, type II collagen, COMP) ¹ is logically complemented by glucosamine, chondroitin, collagen hydrolysate, and vitamin C, which supply matrix precursors, though no co-administration studies exist.

Cartalax has no FDA approval for any indication and no public IND or NDA. It is marketed as a dietary supplement and a parenteral research peptide rather than an approved drug. The DEA does not schedule it under the Controlled Substances Act, and it appears on neither the FDA 503A nor 503B bulks lists, so United States compounding pharmacies cannot lawfully procure or prepare it.

International status

• Russia: registered as a parapharmaceutical or biologically active additive in the Khavinson institute line, sold over the counter domestically.
• European Union: no EMA marketing authorization, orphan designation, or PRIME designation.
• Australia: not ARTG-listed; an unregistered therapeutic good under the Personal Importation Scheme with a prescription, up to a 3-month supply.
• United Kingdom: unlicensed special with no marketing authorization; personal import up to 3 months with a prescription.
• United States: marketed as a dietary supplement and parenteral research peptide; practical sourcing is gray-market research import.

Sports and anti-doping

The published literature does not address WADA status, and USADA and UKAD have no Cartalax-specific cases on record. Class-level scrutiny is elevated, however: reporting on the Russian state doping investigations described administration of Khavinson bioregulators including Epitalon, though Cartalax itself was not named. No WADA-accredited assay targeting AED or Cartalax has been published.

Across published human-cell and human-subject studies of this peptide family, no treatment-related adverse events have been reported. The related tetrapeptide AEDG produced benefits without safety signals in a human biomarker study ¹⁰, and related tripeptides left mitochondrial activity, lysosomal activity, and p16 levels unchanged in human induced neurons, arguing against direct organelle toxicity ¹³. Community use of injectable Cartalax reports transient injection-site reactions, mild early fatigue or sleepiness, and occasional headache, with most users at typical doses reporting no perceptible side effects.

Less common and theoretical effects

• Circadian shifts. AEDG raised urinary melatonin metabolite excretion 1.7-fold and normalized clock gene expression in human subjects ¹⁰; intermittent reports of vivid dreaming and sleep-phase shifts occur during Cartalax courses and typically resolve within days.
• Endocrine effects. Related tetrapeptides altered thyroid structure, function, and hemostatic parameters in hypophysectomized birds ¹²; no human cases are documented.
• Inflammatory flares. AED reduces pro-inflammatory cytokines in chondrocytes ² but stimulates NF-κB expression in some MSC models ⁴, so transient flares in already-inflamed joints are theoretically possible early in a course.
• Fibrotic tendency. AED upregulates collagen I synthesis in aging fibroblasts ³, desirable for cartilage repair but theoretically relevant for anyone with established fibrosis or keloid formation.

Contraindications and unknowns

Practitioner positions treat prior hypersensitivity to bioregulators, pregnancy, and breastfeeding as hard stops, and advise caution with active malignancy, autoimmune arthritides, and therapeutic anticoagulation. No human RCT-grade safety dataset exists; duration beyond 10-to-30-day courses and 2 or 3 annual cycles is unstudied, and immunogenicity, formal drug interactions, and the reversibility of epigenetic changes remain uncharacterized ¹¹.